Speakers

Tangir Ahamed

Principal Scientist

uniQure

Gilles Atlan

Vice President

NF2 BioSolutions

Eduard Ayuso

Head of Innovative Vectorology and Scientific Director of the Translational Vector Core

University of Nantes

Soraya Bekkali

Chief Executive Officer/Venture Partner

Cellinta/SV Health Investors

Michael Binks

Vice President, Rare Disease Clinical Research

Pfizer

Alexandra Brinkman

Lead Research Analyst

Beacon Targeted Therapies

Christina Broomes

Director, Contract Manufacturing

Ultragenyx

Andrea Challand

Director, Regulatory Affairs

Roche

Gabriel Cohn

Chief Medical Officer

Homology Medicines

Pierre-Albert Colcomb

Business Development Director

Genethon

Nick Crabb

Programme Director, Scientific Affairs

National Institute for Health and Care Excellence (NICE)

Claire Davies

Associate Vice President

Sanofi

Jean-Yves Deslandes

Chief Medical Officer

Horama

Anne Douar

Chief Development Officer

Vivet Therapeutics

Ramin Farhood

Vice President, Head of Global Medical Affairs

AveXis

Michela Gabaldo

Head of Alliance Management & Regulatory Affairs

Fondazione Telethon

Magali Gibou

Vice President, Regulatory Affairs

Sangamo Therapeutics

Clare Goddard

Lead & Chair NF2

BioSolutions UK

Grace Hampson

Associate Director Office of Health

Economics

Annie Hubert

Senior Director, European Public Policy

Alliance for Regenerative Medicine

Sven Kili

Principal

Sven Kili Consulting

Kei Kishimoto

Chief Scientific Officer

Selecta Biosciences

Renée Kober

Team Lead Analytical Development

Molecular Biology Freeline Therapeutics

Andreas Kouri

Vice President, Global Supply Chain

bluebird bio

Mahesh Kudari

Senior Medical Director & Program Lead

Orchard Therapeutics

Mindy Leffler

President & Chairman

Casimir

Jim Lennertz

Senior Vice President, Commercial Operations, EUMEA

BioMarin

Lee Markwick

Associate Director, External Development & Manufacturing

Orchard Therapeutics

Parag Meswani

Senior Vice President

Axovant Sciences

Christeen Moburg

Head of Patient Advocacy

Sangamo Therapeutic

Eric Mosbrooker

Senior Vice President & Chief Commercial Officer

Audentes Therapeutics

Shankar Musunuri

Chairman, Chief Executive Officer & Co-Founder

Ocugen

Alexander Natz

Director General

EUCOPE

Stavros Ntogiakos

Head Region Europe Novartis for Gene Therapy (Luxturna)

Novartis

Roland Pach

Project Leader

Roche

Palani Palaniappan

Chief Technology Officer

Aruvant

Samantha Parker

Senior Vice President & Chief Patient Access Officer

Lysogene

Frederick Porter

Senior Vice President, Technical Development and Manufacturing, Gene Therapy

BridgeBio

Tom Pulles

Vice President

Head of Medical Affairs & Patient Advocacy, Europe Ultragenyx

Satinder Rawat

Senior Licensing Officer

University of Massachusetts Medical School

Greg Robertson

EU Patient Advocacy Lead

Spark Therapeutics

Louise Rowe

Program Lead

Orchard Therapeutics

Franz Schnetzinger

Director, Quality Control & CMC Analytical Development

Gyroscope Therapeutics

Simon Shohet

Head of International Market Access

Amicus Therapeutics

Tamir Singer

Head of Commercial Development

NHS England

Magali Taiel

Chief Medical Officer

Gensight Biologics

Jan Wijnholds

Associate Professor

Leiden University Medical Center

Speaker to be Confirmed

Brammer Bio

Speaker to be Confirmed

The Jackson Laboratory

Speaker to be Confirmed

BIA Separations